The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for ...

The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid ...

Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo (nirogacestat) as ...

The European Commission has granted German pharmaceutical giant Merck approval to use the cancer drug Ogsiveo, the ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...

Ogsiveo ™ met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease ...

SpringWorks Therapeutics’ SWTX oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors in November 2023 ...

Corinne Jenkins has given her Buy rating due to a combination of factors surrounding the optimistic outlook for Springworks Therapeutics’s new drug, Ogsiveo. Her confidence is largely influenced ...